<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02947087</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00053906</org_study_id>
    <nct_id>NCT02947087</nct_id>
  </id_info>
  <brief_title>Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis</brief_title>
  <official_title>Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: To describe and compare the safety and efficacy of treatment with AAT in
      chronic pancreatitis patients who undergo total pancreatectomy and islet autotransplantation
      (TP-IAT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to assess whether infusion of Prolastin-C during peri-transplant
      period can enhance islet autograft survival and function in chronic pancreatitis patients who
      have total pancreatectomy and islet autotransplantation. This is a prospective, controlled,
      double-blind study. The primary endpoint will be area under the curve for the serum C-peptide
      level during the first 4 hours of an mixed meal tolerance test (MMTT), normalized by the
      number of islet equivalents (IEQ)/kg at day 365Â±14 after the transplant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Islet graft function</measure>
    <time_frame>365 days</time_frame>
    <description>Islet graft function will be measured by mixed meal tolerance test (MMTT) at 365 days post transplantation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Chronic Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Prolastin-C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be given Prolastin-C intravenously at 60mg/kg weekly for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be given Saline weekly for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prolastin-C</intervention_name>
    <description>Patients will receive Prolastin-C at 60mg/kg on day 0, 7, 14, and 21 days of transplantation</description>
    <arm_group_label>Prolastin-C</arm_group_label>
    <other_name>AAT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive saline on day 0, 7, 14, and 21 days of transplantation</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for total pancreactectomy and islet autotransplantation

          -  Age &gt; 18 years

          -  Diabetes free before surgery

        Exclusion Criteria:

          -  Patients who are under immunosuppression

          -  Patients who have had puestow or frey pancreatic surgery

          -  Patients who have Immunoglobulin A (IgA) deficiency, known antibodies against IgA, or
             individuals with a history of severe immediate hypersensitivity reactions, including
             anaphylaxis to Alpha1-proteinase inhibitor products (allergic to AAT)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongjun Wang, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed Allawi</last_name>
    <phone>843-792-7082</phone>
    <email>allawi@musc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefanie Owczarski</last_name>
    <phone>843-876-4305</phone>
    <email>owczarsm@musc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Allawi</last_name>
      <phone>843-792-7082</phone>
      <email>allawi@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stefanie Owczarski</last_name>
      <phone>843-876-4305</phone>
      <email>owczarsm@musc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Hongjun Wang, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine Morgan, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlie Strange, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Adams, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2016</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Islet autotransplantation</keyword>
  <keyword>Alpha1 anti trypsin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
    <mesh_term>Protein C Inhibitor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

